A team of researchers from the universities of Cambridge and Southampton has created the first vaccine designed entirely by artificial intelligence (AI) to be tested on humans. This innovative vaccine targets a range of viruses, including coronaviruses and Ebola, aiming to provide broader protection against evolving pathogens. Professor Saul Faust, the trial's chief investigator, highlighted the limitations of current reactive vaccine systems, which struggle to keep pace with rapidly mutating viruses. The AI-designed vaccine utilizes a 'super-antigen' that triggers the immune system to recognize multiple viral strains. Notably, it is administered via a microfluidic jet, eliminating the need for needles and making it more suitable for low-resource settings. The initial trial, conducted between December 2021 and September 2023, involved 39 participants and reported no significant safety issues. Following these promising results, researchers will advance to a phase 2 clinical trial to further assess the vaccine's efficacy in a broader population.